NVAX(Novavax, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $1.15B | $1.98B | $983.71M | $682.16M | $1.12B |
| 毛利润 | $1.15B | $1.08B | $639.94M | $479.42M | $1.05B |
| 营业利润 | −$1.69B | −$644.74M | −$566.51M | −$248.93M | $452.80M |
| 净利润 | −$1.74B | −$657.94M | −$545.06M | −$187.50M | $440.30M |
| 经营现金流 | $322.95M | −$415.94M | −$713.97M | −$87.26M | −$244.63M |
| 自由现金流 | $265.46M | −$504.99M | −$767.74M | −$100.32M | −$250.19M |
| 摊薄每股收益 | $-23.44 | $-8.42 | $-5.41 | $-1.23 | $2.58 |